New drug combo offers hope for tough Crohn's cases

NCT ID NCT07510191

First seen Apr 08, 2026 · Last updated May 21, 2026 · Updated 8 times

Summary

This study tests whether adding a low dose of upadacitinib to standard TNF inhibitor therapy works better than increasing the TNF inhibitor dose alone for people with moderate-to-severe Crohn's disease who aren't getting enough benefit from their current treatment. About 312 adults will be randomly assigned to one of two groups and followed for at least 14 weeks to see which approach leads to more symptom relief and fewer side effects. The goal is to find a safer, more effective way to control the disease without needing lifelong high-dose medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.